Superworth

TG Therapeutics profit margin TGTX

Gross, operating and net profit as a share of revenue over the last twelve months, from 2023.

Net margin, 12 months
55.2%
Operating margin, 12 months
17.1%
Net margin on a year earlier
+41.9 pts
Peer median
8.1%

Over the twelve months to Jun 30, 2026, TG Therapeutics kept 55.2% of its revenue as net profit, with an operating margin of 17.1% and a gross margin of 82.4%.

The median for 10 large drugmakers of a similar size is 8.1%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY202572.6%20.0%83.7%
FY20247.1%12.7%88.3%
FY20235.4%8.8%94.0%
FY2022n/an/an/a
FY2021n/an/an/a
FY2020n/an/an/a
FY2019n/an/an/a
FY2018n/an/an/a
FY2017n/an/an/a
FY2016n/an/an/a
FY2015n/an/an/a
FY2014n/an/an/a
FY2013n/an/an/a
FY2012n/an/an/a
FY2011n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY2655.2%+41.9 pts17.1%
Q1 FY2666.0%+55.8 pts21.3%
Q4 FY2572.6%+65.5 pts20.0%
Q3 FY2584.1%+89.6 pts19.3%
Q2 FY2513.3%−14.3 pts18.9%
Q1 FY2510.1%−4.1 pts15.5%
Q4 FY247.1%+1.7 pts12.7%
Q3 FY24−5.4%+8.2 pts−0.2%
Q2 FY2427.6%n/a29.4%
Q1 FY2414.2%n/a16.7%
Q4 FY235.4%n/a8.8%
Q3 FY23−13.7%n/a−10.0%

Against its peers

Companies in Drug Manufacturers - General nearest TG Therapeutics' size, closest first, today.

CompanyProfit margin
TGTXTG Therapeutics55.2%
PTGXProtagonist Therapeutics29.4%
CORTCorcept Therapeutics6.6%
ALKSAlkermes plc.4.0%
AMRXAmneal Pharmaceuticals5.0%
BMRNBiomarin Pharmaceutical2.1%
LGNDLigand Pharmaceuticals67.9%
KNSAKiniksa Pharmaceuticals International9.6%
JAZZJazz Pharmaceuticals20.4%
INDVIndivior Pharmaceuticals26.7%
ARQTArcutis Biotherapeutics6.1%
Peer median8.1%

Where TG Therapeutics ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on TG Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.